ILiAD Biotechnologies LLC, a late-stage biotech development company dedicated to the prevention of disease caused by Bordetella pertussis, has selected Emmes Group, a global contract research and technology organization, to conduct upcoming Phase III studies of its lead pertussis vaccine candidate, BPZE1.
 
ILiAD selected Emmes Group for its expertise in vaccine development, agility in managing complex clinical trials, strong local market presence, and its integrated technology capabilities. Emmes Groups’ VaxTrials unit has previously demonstrated proficiency and clinical trial excellence through its successful support of ILiAD’s Phase II IB-201P BPZE1 study.
 
Dr. Keith Rubin, CEO of ILiAD Biotechnologies, commented, “Selecting Emmes Group for our Phase III BPZE1 trials has been a carefully considered strategic decision to ensure the highest standards of clinical research. VaxTrials’ specialization in vaccines and Veridix AI’s advanced technological capabilities will be instrumental in executing our BPZE1 vaccine clinical development plan.”
 
“We are honored and pleased that ILiAD has selected Emmes Group as its partner to continue the clinical development of BPZE1. We look forward to working closely with ILiAD’s clinical development team on this promising new vaccine, which could significantly reduce the transmissibility and incidence of B. pertussis, particularly in vulnerable populations,” said Sastry Chilukuri, CEO of Emmes Group.